Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic)

Phase 1Biologic

Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic) is one of 37 biologic programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Imjudo

AstraZeneca

Preclinical

5 6

Vizimpro

Pfizer

Preclinical

4 7

Gilotrif

Boehringer Ingelheim

Preclinical

12 8

Ofev

Boehringer Ingelheim

Preclinical

7 9

Immunotherapy

Remeron

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer

Enrolling by invitation·BBiogenea Pharmaceuticals Ltd.·Phase 1·NCT07285434·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogenea Pharmaceuticals Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: BBiogenea Pharmaceuticals Ltd.

Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News